(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089835 A3

(51) International Patent Classification[7]: A61K 38/55, 9/20, A61P 31/12, 31/18

(21) International Application Number: PCT/EP02/04711

(22) International Filing Date: 29 April 2002 (29.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/288,410 3 May 2001 (03.05.2001) US

(71) Applicant: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; 124 Grenzacharstrasse, CH-4070 Basel (CH).

(72) Inventors: **INFELD, Martin, Howard**; 6 Tuers Place, Upper Montclair, NJ 07043 (US). **PHUAPRADIT, Wantanee**; 42 Robinson Terrace, Clifton, NJ 07013 (US). **SHAH, Navnit, Hargovindas**; 203 Beverly Hill Road, Clifton, NJ 07012 (US). **ZHANG, Lin**; 900 Davidson Road, Apartment 56, Piscataway, NJ 08854 (US).

(74) Agent: **RAUBER, Beat**; 124 Grenzacherstrasse, CH-4070 Basel (CH).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

[Continued on next page]

(54) Title: PHARMACEUTICAL DOSAGE FORM OF AMORPHOUS NELFINAVIR MESYLATE



(57) Abstract: A solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate is provided comprising amorphous nelfinavir mesylate, and a pharmaceutically acceptable, water soluble, non-ionic synthetic block copolymer of ethylene oxide and propylene oxide, said copolymer having a melting point of at least 40°C. A hot melt granulation process for making the dosage form is provided.

WO 02/089835 A3

(88) Date of publication of the international search report:
1 May 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.